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George S. Stergiou, MD
I N T R O D U C T I O N
Evidence-based medicine suggests that practice hypertension guidelines should be 
primarily based on the evidence from large outcome trials [1-5]. However, new data 
appear in the literature every day. In 2005 a total of 63,286 publications that included 
the keyword “hypertension” appeared in the MedLine, of which 2,484 were reports of 
clinical trials. Only few of these trials are expected to change current recommenda-
tions for the management of hypertension in clinical practice. This document presents 
several issues in the current hypertension guidelines that the author believes need to 
be modified mainly because of new information from recent clinical trials.
F I R S T  L I N E  A N T I H Y P E R T E N S I V E  D R U G S
There is general agreement between European and American guidelines regarding 
the choice of first line drugs in hypertension [1-2]. Diuretics, â-blockers, angiotensin 
converting enzyme (ACE) inhibitors, calcium antagonists and angiotensin receptor 
blockers are recommended as first line treatment in hypertension. The only differ-
ence between guidelines is that the US JNC-7 placed diuretics a small step ahead (to 
be administered in most of patients) [5]. In 2005, a metaanalysis of 13 randomized 
controlled outcome trials that included 105,951 patients, questioned the efficacy of 
â-blockers in preventing cardiovascular events and suggested that these drugs should 
be regarded as second line antihypertensive treatment [6]. This metaanalysis showed 
significantly lower efficacy of â-blockers compared to other drugs in preventing stroke. 
A previous metaanalysis also showed reduced cardiovascular protection with â-blockers 
in the elderly [7] and in the Canadian Hypertension Guidelines 2005 these drugs are 
not recommended as first line treatment in the elderly [3]. These data do not diminish 
the usefulness of â-blockers in their compelling indications, such as post myocardial 
infarction, in heart failure, angina, tachyarrhythmia, etc.
C H O I C E  O F  A N T I H Y P E R T E N S I V E  D R U G  T R E A T M E N T  
A N D  N E W  O N S E T  D I A B E T E S
A series of outcome trials designed to compare the efficacy of several antihyperten-
sive drug classes consistently showed that the incidence of new onset diabetes within 
2-5 years is by 20-30% less common in subjects on treatment based on renin-angio-
tensin system blockers (ACE inhibitors or angiotensin receptor blockers) compared 
to other drugs [8-10]. The available evidence suggests that this difference is due to a 
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protective effect of renin-angiotensin system blockers as well 
as a detrimental effect of the other drugs (â-blockers and di-
uretics). It should be taken into account that, in the majority 
of the trials, the protective effect of renin-angiotensin system 
blockers was evident even when these drugs were co-admin-
istered with low-dose diuretics [11].
These data suggest that in subjects at increased risk 
of diabetes development (pre-diabetics or with metabolic 
syndrome), treatment should be based on renin-angiotensin 
system blockers and other drugs might be added if needed to 
achieve optimal blood pressure control. In these subjects, the 
â-blocker-diuretic combination should be regarded as second 
line treatment, unless there is a compelling indication for the 
administration of these drugs.
C O M B I N A T I O N  T H E R A P Y  
I N  H Y P E R T E N S I O N
Combination pharmacotherapy is essential for the op-
timal blood pressure control in most hypertensive patients. 
Scientific societies should develop clear guidelines regarding 
the use of two-drug and three-drug combinations, which are 
widely used in clinical practice. The role of the â-blocker-di-
uretic combination as first line combination therapy should 
be reconsidered (see “First line antihypertensive drugs” and 
“Choice of antihypertensive drug treatment and new onset 
diabetes”). Detailed recommendations are also needed for the 
role of fixed-dose combinations and for treatment initiation 
with drug combination. The American guidelines recommend 
treatment initiation with two drugs in subjects with stage-2 
hypertension (blood pressure ≥160/100 mmHg) and in those 
with blood pressure >200/100 mmHg above the recommended 
goal (e.g. subjects with diabetes and/or renal disease and blood 
pressure ≥150/90 mmHg) [2]. The European guidelines also 
endorsed treatment initiation with combination, but gave a 
rather unclear indication, that is to be applied on the basis of 
the blood pressure level and total cardiovascular risk [1]. Treat-
ment initiation with combination is being widely used in clini-
cal practice well before it was recommended by Hypertension 
Societies. The European guidelines should provide a detailed 
proposal regarding this issue, as well as for the preference of 
low doses and the avoidance of overestimation of the blood 
pressure level that can lead to overtreatment.
F A S T  B L O O D  P R E S S U R E  C O N T R O L  I N  
H I G H - R I S K  P A T I E N T S
The recent outcome trial VALUE [9], which was designed 
to compare the efficacy of an angiotensin receptor blocker 
(valsartan) with a calcium antagonist (amlodipine) in hyper-
tensive patients with high total cardiovascular risk, showed 
that the cardiovascular risk was significantly lower in subjects 
in whom blood pressure was effectively controlled within the 
first 6 months, compared to those not controlled. Interestingly, 
this benefit was independent of the drug class (valsartan or 
amlodipine). It should be noted, however, that the majority 
of patients in the VALUE trial were treated before the study, 
and treatment was withdrawn for study entry. Therefore, this 
study does not directly address the issue of the significance 
of fast blood pressure control, but rather the importance of 
retaining steady and effective control.
These data suggest that, specifically in hypertensive 
patients at high cardiovascular risk, blood pressure control 
should be achieved without delay and blood pressure should 
remain at optimal levels. Treatment initiation with two drugs 
should be considered in these patients, particularly if blood 
pressure is >200/100 mmHg above the recommended goal 
(see “Combination therapy in hypertension”). However, when 
blood pressure is close to the target, treatment should be care-
fully titrated to prevent symptomatic overtreatment.
S T A T I N S  I N  H Y P E R T E N S I V E  S U B J E C T S  
W I T H  M U L T I P L E  C A R D I O V A S C U L A R  
R I S K  F A C T O R S
In the ASCOT-LLA outcome trial [12] 10,305 hyperten-
sive subjects with no history of coronary heart disease, total 
cholesterol ≤250 mg/dl, triglycerides ≤400 mg/dl and 3 ad-
ditional cardiovascular risk factors (age ≥55 years, male sex, 
type 2 diabetes, family history of premature coronary heart 
disease, left ventricular hypertrophy, peripheral artery disease, 
microalbuminuria or proteinuria, history of stroke or transient 
ischemic attack) were randomized to treatment with a statin 
(atorvastatin 10 mg) or placebo. The study was discontinued 
after 3.5 years of follow-up (before its prescheduled end) 
because of a statistically significant and clinically important 
benefit in the atorvastatin arm (reduction in coronary as well 
as stroke events by about 30%) [12]. Interestingly, this ben-
efit appeared early and was independent of cholesterol levels 
at baseline. In addition, there was a positive interaction of 
atorvastatin, regarding the cardiovascular protection, with 
amlodipine but not atenolol (patients were also random-
ized to antihypertensive treatment based on amlodipine or 
atenolol) [10].
In 2005 the Canadian Society of Hypertension translated 
the ASCOT-LLA study findings into practice guidelines [3]. 
In the strategy for global vascular protection, recommenda-
tions are given for the use of (a) aspirin in hypertensive sub-
jects with controlled blood pressure and (b) statin in certain 
non-hyperlipidemic hypertensive subjects with established 
atherosclerotic disease or with 3 additional cardiovascular 
risk factors as mentioned above.
210
HOSPITAL CHRONICLES, SUPPLEMENT 2006 HYPERTENSION GUIDELINES: WHAT IS EXPECTED TO CHANGE IN 2006
211
M A S K E D  H Y P E R T E N S I O N
The term “masked hypertension” has been recently intro-
duced to describe subjects with normal blood pressure in the 
clinic but elevated home or ambulatory blood pressure, namely 
hypertension that is hidden until out-of-office blood pressure 
is assessed [14]. Studies have shown that subjects with masked 
hypertension have similar left ventricular mass and carotid 
wall thickness as the untreated hypertensives [15]. The recent 
outcome study SHEAF in 4,939 treated elderly hypertensives 
in France showed that masked hypertensives (diagnosed on 
the basis of office and home blood pressure measurements) 
have the same risk for cardiovascular disease as the untreated 
hypertensives [16].
These data suggest that in subjects with masked hyper-
tension the decision to treat and the achievement of blood 
pressure control should be primarily based on out-of-office 
blood pressure measurements (at home or with ambulatory 
monitoring). As is the case for the phenomenon of “isolated 
office” or “white coat” hypertension, where again manage-
ment decisions are based primarily on out-of-office blood 
pressure measurement, necessary prerequisites are (a) reliable 
assessment of out-of-office blood pressure (accurate device, 
appropriate measurement conditions, correct measurement 
technique) and (b) confirmation of elevated out-of-office 
blood pressure after a few weeks or months by using the 
same or the alternative measurement technique (home or 
ambulatory blood pressure monitoring).
H O M E  B L O O D  P R E S S U R E  M O N I T O R I N G
The phenomena of “masked hypertension” and “isolated 
office” or “white coat” hypertension are observed in about 
30% of subjects attending an outpatient clinic or office for 
elevated blood pressure [14]. For the evaluation of these cases 
the assessment of out-of-office blood pressure is essential. 
Home blood pressure monitoring is widely available, cheap 
and well accepted by patients [17]. Therefore, it is a valuable 
and cost-effective technique for the evaluation of both “white 
coat” and “masked hypertension” [17].
The European Society of Hypertension Guidelines en-
dorse the application of home blood pressure monitoring in 
clinical practice and recommend the use of reliable electronic 
devices that measure blood pressure at the arm (not the wrist) 
[14]. Given the need for complementary assessment of blood 
pressure with out-of-office measurements in many patients, 
hypertension guidelines should provide clear and detailed rec-
ommendations regarding the few accurate devices for home 
blood pressure monitoring available on the market (for list 
see  [18] and ), as 
well as the optimal home blood pressure monitoring schedule 
for decision making (duplicate morning and evening mea-
surements for 7 work days) and for long-term follow up (one 
measurement per week) [14,17].
B L O O D  P R E S S U R E  G O A L
The recent hypertension guidelines recommend a blood 
pressure goal of <140/90 mmHg to be reached in all hyperten-
sive subjects irrespective of their age, and <130/80 mmHg in 
those with diabetes and/or renal damage [1-5]. Recent studies 
in patients with established coronary heart disease treated 
with calcium antagonists [19] or ACE inhibitors [20] and in 
subjects with a history of stroke treated with an ACE inhibi-
tor and a diuretic [21] showed that aggressive blood pressure 
reduction at levels well below the conventional 140/90 mmHg 
goal is associated with significant additional cardiovascular 
protection.
Although the abovementioned studies were not designed 
to define the optimal blood pressure goal in these patients, 
they suggest that, when the total cardiovascular risk is high, 
the blood pressure goal should be <130/80 mmHg or lower, 
and it does not really matter whether the high risk is due to 
diabetes, renal damage, cardiovascular disease, or coexistence 
of multiple cardiovascular risk factors. The 2003 European 
Society of Hypertension guidelines recommend in high risk 
subjects early initiation of antihypertensive drug treatment at 
blood pressure levels >130/85 mmHg. Blood pressure goal in 
all high risk hypertensives should be <130/80 mmHg.
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